Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia

This study has been completed.

Sponsor:

Information provided by:

Forest Laboratories

ClinicalTrials.gov Identifier:

NCT00110968

First received: May 16, 2005

Last updated: February 6, 2017

Last verified: February 2017

History of Changes

Purpose

Itopride is a compound already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton. It is used to treat symptoms of functional dyspepsia. Patients suffering from this condition have difficulties digesting food. Patients feel full after eating, they have bloating and have stomach pain. The goal of this study is to see if Itopride helps to relieve the symptoms of functional dyspepsia on a long-term basis.

Condition	Intervention	Phase
Dyspepsia	Drug: Itopride hydrochloride	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment
Official Title:	A Multicentre, Open-label Extension Phase to Study the Long-term Safety and Efficacy of Itopride HCl in Patients Suffering From Functional Dyspepsia

Resource links provided by NLM:

MedlinePlus related topics: Indigestion

U.S. FDA Resources

Further study details as provided by Forest Laboratories:

Primary Outcome Measures:

Long-term safety

Secondary Outcome Measures:

Long-term relief of symptoms


Estimated Enrollment:	300
Study Start Date:	September 2004
Study Completion Date:	September 2006
Primary Completion Date:	July 2006 (Final data collection date for primary outcome measure)

Detailed Description:

All patients having completed study ITOFD04-01 will be offered to continue to be treated with itopride for a period of up to one year in duration. A target of 300 patients will be followed up for 6 months. Of these, a target of 100 patients will be kept on treatment for an additional 6 months.

Patients will need to come to the clinic for evaluations every 8 weeks during the trial. Evaluations done at these visits will include: lab tests, evaluation of the heartburn condition, and a questionnaire needed to be completed by the patient to see if the drug is helpful in relieving their symptoms.

Eligibility


Ages Eligible for Study:	18 Years to 65 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients must have completed the 8 week double-blind study ITOFD04-01
Female patients must not be pregnant (must have a negative serum pregnancy test)

Exclusion Criteria:

Patients with any newly occurring medical condition which was an exclusion criterion at ITOFD04-01 study entry

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00110968

Sponsors and Collaborators

Forest Laboratories

Investigators


Principal Investigator:	Nicholas Talley, MD, PhD	Mayo Clinic, Rochester, Minn

More Information


Responsible Party:	Monique Giguère, Axcan Pharma inc.
ClinicalTrials.gov Identifier:	NCT00110968 History of Changes
Other Study ID Numbers:	ITOFD04-02
Study First Received:	May 16, 2005
Last Updated:	February 6, 2017

Keywords provided by Forest Laboratories:


Abdominal Symptom relief Fullness Bloating Indigestion Functional dyspepsia

Additional relevant MeSH terms:


Dyspepsia Signs and Symptoms, Digestive Signs and Symptoms

ClinicalTrials.gov processed this record on August 23, 2017

To Top